grant
Inflammatory and Mitochondrial Plasticity in Neuroendocrine Prostate Cancer
Organization THOMAS JEFFERSON UNIVERSITYLocation PHILADELPHIA, UNITED STATESPosted 6 Mar 2026Deadline 28 Feb 2031
NIHUS FederalResearch GrantFY2026Androgen AntagonistsAndrogen ReceptorAndrogenic AgentsAndrogenic CompoundsAndrogensAnti-AndrogenAnti-Androgen AgentsBeta Proprotein Interleukin 1BioenergeticsBone MetastasisBone cancer metastaticBony metastasisCarcinomaCell BodyCell Communication and SignalingCell LocomotionCell MigrationCell MovementCell SignalingCell membraneCell-Extracellular MatrixCellsCellular MigrationCellular MotilityClinicClinicalCollaborationsCompetenceComplexCredentialingCytoplasmic MembraneDependenceDevelopmentDiagnosisDiseaseDisease ProgressionDisorderDrug TherapyDrug resistanceECMER stressEndowmentEpithelial cancerExhibitsExposure toExtracellular MatrixFibroblastsGene TranscriptionGeneticGenetic TranscriptionHistoryIL-1 betaIL-1 βIL-1-bIL-1βIL1-BetaIL1-βIL1B ProteinIL1F2IL1βImmuneImmunesImmunomodulationIncidenceInflammatoryInner mitochondrial membraneIntegrinsIntegrins Extracellular MatrixInterferon Type IInterleukin 1betaInterleukin-1 betaInterleukin-1βIntermediary MetabolismInterruptionIntracellular Communication and SignalingInvadedInvestigatorsKinasesLife ExpectancyLymphoidLymphoid CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant neoplasm of prostateMalignant prostatic tumorMetabolic ProcessesMetabolismMetastasisMetastasis to boneMetastasizeMetastatic Cancer to the BoneMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Neoplasm to the BoneMetastatic Prostate CancerMetastatic TumorMetastatic Tumor to the BoneMetastatic malignant neoplasm to boneMitochondriaMitochondrial Membrane ProteinModalityMolecularMotilityMyelogenousMyeloidMyeloid CellsNeoplasm Circulating CellsNeoplasm MetastasisNeuroendocrineNeuroendocrine Prostate CancerNeuroendocrine SystemNeurosecretory SystemsOrganellesOsseous metastasisOutcomePDX modelPalliative CarePalliative TherapyPalliative TreatmentPathway interactionsPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmacological TreatmentPharmacotherapyPhenotypePhosphotransferase GenePhosphotransferasesPlasma MembranePreinterleukin 1 BetaProductionProstate CAProstate CancerProstate Carcinoma MetastaticProstate malignancyProtein CleavageProteolysisRNA ExpressionReceptor SignalingRecording of previous eventsRecurrenceRecurrentRegimenResearchResearch PersonnelResearchersResistanceRoleScaffolding ProteinSecondary NeoplasmSecondary TumorSecondary cancer of boneSecondary malignancy of boneSecondary malignant neoplasm of boneShapesSignal TransductionSignal Transduction SystemsSignalingSkeletal metastasisSpecific qualifier valueSpecifiedTherapeutic AndrogenTitrationsTranscriptionTransphosphorylasesTumor CellTumor Cell InvasionTumor InvasionVariantVariationVisceraladvanced prostate cancerandrogen ablation therapyandrogen blockade therapyandrogen deprivation therapyandrogen deprivation treatmentandrogen inhibitoranti-cancer researchbiological adaptation to stressbiological signal transductionbonebone neoplasm secondarycancer metastasiscancer microenvironmentcancer researchcell killingcell motilitycirculating neoplastic cellcirculating tumor cellcomfort carecytokinedeprivationdevelopmentaldisease modeldisorder modeldrug interventiondrug resistantdrug treatmentendoplasmic reticulum stressepithelial carcinomaexperimentexperimental researchexperimental studyexperimentsfitnessgenetic approachgenetic strategyglobal gene expressionglobal transcription profilehistorieshormonal signalshormone signalsimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimprovedin vivoinhibitormitochondrialmitochondrial dysfunctionneoplastic cellneutralizing mAbneutralizing monoclonal antibodiesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetpalliative interventionpathwaypatient derived xenograft modelpatient oriented outcomespharmaceutical interventionpharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsplasmalemmapre-clinicalpreclinicalpressurepreventpreventingprogramsprostate cancer metastasisprostate cancer modelprostate cancer progressionprostate tumor modelreaction; crisisrecruitresistance to Drugresistance to therapyresistantresistant to Drugresistant to therapyresponseresponse to therapyresponse to treatmentrho G-Proteinsrho GTP-Binding Proteinsrho GTPasesrho Protein P21rho Small GTP-Binding Proteinssenescence and its associated secretory phenotypesenescence associated secretomesenescence associated secretory factorssenescence associated secretory pathwaysenescence associated secretory phenotypesenescence associated secretory programsenescence associated secretory proteinssenescent associated secretomesenescent associated secretory phenotypeskeletalsmall moleculesocial rolespatial and temporalspatial temporalspatiotemporalstress kinasestress responsestress; reactionsynergismtherapeutic resistancetherapeutic responsetherapeutic targettherapy resistanttherapy responsetraittranscriptometreatment resistancetreatment responsetreatment responsivenesstumortumor cell metastasistumor microenvironment
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY
Potent antagonists of androgen and androgen receptor (AR) signaling have revolutionized the treatment of
recurrent prostate cancer (PrCa). Despite initial responses, all patients eventually become resistant to
treatment, but in approximately 20% of the cases, and perhaps more, the disease evolves in response to
therapy to a new,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click